- Investing Ideas
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
54
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
54 companies
Madrigal Pharmaceuticals
Market Cap: US$10.0b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$435.01
7D
-6.4%
1Y
29.4%
Travere Therapeutics
Market Cap: US$2.8b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$30.39
7D
9.2%
1Y
38.3%
Arcutis Biotherapeutics
Market Cap: US$3.1b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$25.42
7D
-1.7%
1Y
95.2%
Insmed
Market Cap: US$35.5b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$164.91
7D
10.9%
1Y
103.4%
Ardelyx
Market Cap: US$1.4b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.73
7D
-16.6%
1Y
13.2%
Marker Therapeutics
Market Cap: US$24.2m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$1.45
7D
1.4%
1Y
-7.6%
Cogent Biosciences
Market Cap: US$6.0b
A clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
COGT
US$37.34
7D
2.2%
1Y
366.8%
RenovoRx
Market Cap: US$33.5m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.91
7D
-2.2%
1Y
-11.4%
Soleno Therapeutics
Market Cap: US$2.1b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$39.36
7D
5.7%
1Y
-14.7%
Aldeyra Therapeutics
Market Cap: US$297.8m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$4.95
7D
-6.3%
1Y
-26.0%
ARS Pharmaceuticals
Market Cap: US$889.6m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$9.00
7D
1.7%
1Y
-19.9%
Achieve Life Sciences
Market Cap: US$227.3m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.27
7D
1.7%
1Y
34.7%
Capricor Therapeutics
Market Cap: US$1.5b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$28.51
7D
27.0%
1Y
90.1%
Lineage Cell Therapeutics
Market Cap: US$438.6m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$1.81
7D
9.0%
1Y
167.8%
Pelthos Therapeutics
Market Cap: US$75.2m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$23.24
7D
12.9%
1Y
38.3%
Precigen
Market Cap: US$1.5b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$4.38
7D
-11.2%
1Y
129.3%
Syndax Pharmaceuticals
Market Cap: US$1.7b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$19.69
7D
-3.9%
1Y
20.2%
Viridian Therapeutics
Market Cap: US$2.6b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$27.44
7D
-1.6%
1Y
68.7%
Caris Life Sciences
Market Cap: US$5.5b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$19.53
7D
-5.3%
1Y
n/a
CollPlant Biotechnologies
Market Cap: US$8.9m
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
CLGN
US$0.62
7D
-14.5%
1Y
-82.3%
AC Immune
Market Cap: US$249.3m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.52
7D
-15.7%
1Y
-4.9%
NewAmsterdam Pharma
Market Cap: US$4.1b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$35.58
7D
2.7%
1Y
91.6%
Vera Therapeutics
Market Cap: US$3.0b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
VERA
US$41.76
7D
-1.1%
1Y
46.1%
Altimmune
Market Cap: US$548.5m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$4.38
7D
-3.3%
1Y
-31.9%
Ocugen
Market Cap: US$524.6m
A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.
OCGN
US$1.60
7D
13.5%
1Y
135.3%
Praxis Precision Medicines
Market Cap: US$9.3b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$335.28
7D
5.7%
1Y
350.1%
Rhythm Pharmaceuticals
Market Cap: US$6.7b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$99.78
7D
1.7%
1Y
78.0%
Unicycive Therapeutics
Market Cap: US$135.0m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$6.28
7D
1.3%
1Y
1.8%
Anavex Life Sciences
Market Cap: US$381.8m
Operates as a biopharmaceutical company.
AVXL
US$4.12
7D
4.8%
1Y
-50.7%
Ionis Pharmaceuticals
Market Cap: US$13.5b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$83.15
7D
3.2%
1Y
157.3%
Mirum Pharmaceuticals
Market Cap: US$6.3b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$105.16
7D
2.0%
1Y
100.5%
Fortress Biotech
Market Cap: US$104.3m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$3.36
7D
-6.9%
1Y
107.4%
Amicus Therapeutics
Market Cap: US$4.5b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$14.34
7D
0.2%
1Y
56.0%
Creative Medical Technology Holdings
Market Cap: US$6.6m
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
CELZ
US$1.90
7D
2.2%
1Y
-64.8%
Savara
Market Cap: US$1.4b
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
SVRA
US$5.53
7D
-1.3%
1Y
105.6%
Day One Biopharmaceuticals
Market Cap: US$1.2b
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$11.78
7D
3.8%
1Y
-5.2%